M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera PharmaphorumJazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaphorum Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls shortNext: Next Post Related Stories M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026 M&A / Deals Altaris to acquire Simulations Plus in $375m all-cash deal pharminent June 17, 2026 M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
